RU2010145995A - MEANS OF REDUCING MAMMAL ANXIETY, METHOD OF REDUCING ANXIETY, APPLICATION OF DELTA-OPIOID RECEPTOR ANTAGONISTS THAT DO NOT APPLY THROUGH HEMATO-ENCEPHALIC BARRIEROUS - Google Patents

MEANS OF REDUCING MAMMAL ANXIETY, METHOD OF REDUCING ANXIETY, APPLICATION OF DELTA-OPIOID RECEPTOR ANTAGONISTS THAT DO NOT APPLY THROUGH HEMATO-ENCEPHALIC BARRIEROUS Download PDF

Info

Publication number
RU2010145995A
RU2010145995A RU2010145995/15A RU2010145995A RU2010145995A RU 2010145995 A RU2010145995 A RU 2010145995A RU 2010145995/15 A RU2010145995/15 A RU 2010145995/15A RU 2010145995 A RU2010145995 A RU 2010145995A RU 2010145995 A RU2010145995 A RU 2010145995A
Authority
RU
Russia
Prior art keywords
anxiety
reducing
delta
mammal
opioid receptor
Prior art date
Application number
RU2010145995/15A
Other languages
Russian (ru)
Other versions
RU2470661C2 (en
Inventor
Сергей Константинович Судаков (RU)
Сергей Константинович Судаков
Валентина Германовна Башкатова (RU)
Валентина Германовна Башкатова
Галина Алексеевна Назарова (RU)
Галина Алексеевна Назарова
Ксения Николаевна Колясникова (RU)
Ксения Николаевна Колясникова
Original Assignee
Учреждение Российской академии медицинских наук Научно-исследовательский институт нормальной физиологии имени П.К. Анохина РАМН (RU)
Учреждение Российской академии медицинских наук Научно-исследовательский институт нормальной физиологии имени П.К. Анохина РАМН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Учреждение Российской академии медицинских наук Научно-исследовательский институт нормальной физиологии имени П.К. Анохина РАМН (RU), Учреждение Российской академии медицинских наук Научно-исследовательский институт нормальной физиологии имени П.К. Анохина РАМН filed Critical Учреждение Российской академии медицинских наук Научно-исследовательский институт нормальной физиологии имени П.К. Анохина РАМН (RU)
Priority to RU2010145995/15A priority Critical patent/RU2470661C2/en
Publication of RU2010145995A publication Critical patent/RU2010145995A/en
Application granted granted Critical
Publication of RU2470661C2 publication Critical patent/RU2470661C2/en

Links

Abstract

1. Средство снижения уровня тревожности млекопитающего, характеризующееся тем, что оно содержит антагонист дельта-опиоидных рецепторов, не проникающий через гемато-энцефалический барьер. ! 2. Способ снижения уровня тревожности, характеризующийся тем, что млекопитающему перорально вводят антагонист дельта-опиоидных рецепторов, не проникающий через гемато-энцефалический барьер. ! 3. Применение антагонистов дельта-опиоидных рецепторов, не проникающих через гемато-энцефалический барьер, для приготовления средства снижения уровня тревожности млекопитающего. 1. A means of reducing the anxiety level of a mammal, characterized in that it contains a delta-opioid receptor antagonist that does not penetrate the blood-brain barrier. ! 2. A method of reducing anxiety, characterized in that the mammal is orally administered a delta-opioid receptor antagonist that does not cross the blood-brain barrier. ! 3. The use of antagonists of delta opioid receptors that do not penetrate the blood-brain barrier to prepare a means of reducing the level of anxiety in a mammal.

Claims (3)

1. Средство снижения уровня тревожности млекопитающего, характеризующееся тем, что оно содержит антагонист дельта-опиоидных рецепторов, не проникающий через гемато-энцефалический барьер.1. A means of reducing the anxiety level of a mammal, characterized in that it contains a delta-opioid receptor antagonist that does not penetrate the blood-brain barrier. 2. Способ снижения уровня тревожности, характеризующийся тем, что млекопитающему перорально вводят антагонист дельта-опиоидных рецепторов, не проникающий через гемато-энцефалический барьер.2. A method of reducing anxiety, characterized in that the mammal is orally administered a delta-opioid receptor antagonist that does not cross the blood-brain barrier. 3. Применение антагонистов дельта-опиоидных рецепторов, не проникающих через гемато-энцефалический барьер, для приготовления средства снижения уровня тревожности млекопитающего. 3. The use of antagonists of delta opioid receptors that do not penetrate the blood-brain barrier to prepare a means of reducing the level of anxiety in a mammal.
RU2010145995/15A 2010-11-11 2010-11-11 Method for reducing mammalian anxiety level, method for reducing anxiety level, use of delta-opioid receptor antagonists not penetrating through brain-blood barrier for preparing anxiolytic agents RU2470661C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2010145995/15A RU2470661C2 (en) 2010-11-11 2010-11-11 Method for reducing mammalian anxiety level, method for reducing anxiety level, use of delta-opioid receptor antagonists not penetrating through brain-blood barrier for preparing anxiolytic agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010145995/15A RU2470661C2 (en) 2010-11-11 2010-11-11 Method for reducing mammalian anxiety level, method for reducing anxiety level, use of delta-opioid receptor antagonists not penetrating through brain-blood barrier for preparing anxiolytic agents

Publications (2)

Publication Number Publication Date
RU2010145995A true RU2010145995A (en) 2012-10-27
RU2470661C2 RU2470661C2 (en) 2012-12-27

Family

ID=47146812

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010145995/15A RU2470661C2 (en) 2010-11-11 2010-11-11 Method for reducing mammalian anxiety level, method for reducing anxiety level, use of delta-opioid receptor antagonists not penetrating through brain-blood barrier for preparing anxiolytic agents

Country Status (1)

Country Link
RU (1) RU2470661C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2580311C1 (en) * 2014-12-26 2016-04-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной генетики Российской академии наук Antianxiety drugs and pharmaceutical compositions with anxiolytic effects

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2161500C1 (en) * 1999-07-06 2001-01-10 Институт молекулярной генетики РАН Heptapeptide with adaptogenic and anxiolytic activity
RU2196579C2 (en) * 2001-02-08 2003-01-20 Амурская государственная медицинская академия Method for decreasing level of anxiety in laboratory animals during an experiment
RU2007134356A (en) * 2007-09-14 2009-03-20 ГОСУДАРСТВЕННОЕ ОБРАЗОВАТЕЛЬНОЕ УЧРЕЖДЕНИЕ ВЫСШЕГО ПРОФЕССИОНАЛЬНОГО ОБРАЗОВАНИЯ АМУРСКАЯ ГОСУДАРСТВЕННАЯ МЕДИЦИНСКАЯ АКАДЕМИЯ Росздрава (RU) METHOD FOR REDUCING ANXIETY LEVEL IN EXPERIMENT
RU2398761C2 (en) * 2008-06-16 2010-09-10 Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) Anxiolytics

Also Published As

Publication number Publication date
RU2470661C2 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
FR20C1022I2 (en) DOSAGE OF AN S1P RECEPTOR AGONIST
EA201290355A1 (en) SPYROPYPERIDINE CONNECTIONS AS ANTAGONISTS OF ORL-1 RECEPTOR
EA201390977A1 (en) COMBINATION OF OPIOID RECEPTOR AGONIST AND OPIOID RECEPTOR ANTAGONIST FOR THE TREATMENT OF PARKINSON'S Disease
PE20141171A1 (en) ORAL PHARMACEUTICAL DOSAGE FORM RESISTANT TO ALTERATION INCLUDING OPIOID AGONIST AND OPIOID ANTAGONIST
BRPI1008060A2 (en) S1p5 receptor agonists and antagonists, and methods of use thereof.
HK1188211A1 (en) Cxcr4 receptor antagonists cxcr4
CR20140182A (en) NEW CYCLOHEXYLAMINE DERIVATIVES THAT HAVE ACTIVITY AS ADRENERGIC B2 AGONISTS AND AS M3 MUSCARINIC ANTAGONISTS
ECSP12012213A (en) NEW CYCLOHEXYLAMINE DERIVATIVES THAT HAVE ACTIVITY AS ADRENERGIC AGONISTS? 2 AND AS M3 MUSCARINIC ANTAGONISTS
AU2011234398A8 (en) Novel NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
BR112014014547A2 (en) e-selectin antagonist compounds, compositions and methods of use
SMT201600164B (en) NEW N-ACYL-5, 6, 7, (8-SODSTITUTED) -TETRAIDRO- [1, 2, 4] TRIAZOL [4, 3-A] CHIRAL PIRAZINES AS SELECTIVE ANTAGONISTS OF THE NK-3 RECEPTOR, PHARMACEUTICAL COMPOSITION, AND METHODS FOR USE IN DISORDERS MEDIATED BY NK-3 RECEPTOR
ECSP14013340A (en) NEW CYCLOHEXYLAMINE DERIVATIVES THAT HAVE ACTIVITY AS ADRENERGIC AGONISTS? 2 AND AS M3 MUSCARINIC ANTAGONISTS
HK1187045A1 (en) Buprenorphine analogs as opioid receptor agonists and or antagonists
MY160665A (en) Spiropiperidine compounds as orl-1 receptor antagonists
SMT201700064B (en) D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE
EA201391662A1 (en) CONNECTIONS WITH THE ACTIVITY OF ANTAGONISTS OF MUSCARINE RECEPTORS AND AGONISTS OF THE ADRENERGIC RECEPTOR BETA2
DK2252581T3 (en) CAPE-SELECTIVE OPIOID RECEPTOR ANTAGONIST
MA32301B1 (en) 1-aryl-3-amine-coccyberazole as a sigma bond increases the analgesic effect of opioids by reducing dependence on the latter
DK3312169T3 (en) 5-HT3 RECEPTOR ANTAGONISTS
EA201491153A1 (en) COMPOSITIONS OF BUPRENORPHINE AND ANTAGONISTS OF μ-OPIOID RECEPTORS
UY35776A (en) ? ANTAGONISTAS RECEPTOR EP3 PROSTAGLANDINA ?.
CL2012000263A1 (en) Compounds derived from spirocyclic amides, b-adrenoreceptor agonist and muscarinic antagonist; useful in the treatment of inflammatory diseases, such as COPD.
CL2013000502A1 (en) Compounds derived from-2- (1- (2 (2-carbonyl-ethyl) benzyl) pyrrolidin-2-yl) -n-alkyloxazole-4-carboxamide; use in the treatment of diseases involved with the anti-inflammatory response in prostaglandin receptors.
EA201390653A1 (en) AA ANTAGONISTS AS AMPLIFIERS OF COGNITIVE AND MOTOR FUNCTIONS
FR2965612B1 (en) DEVICE FOR MEASURING THE EVOLUTION OF A CRACK, IN PARTICULAR A BUILDING WALL

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20181112